News

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...
Vaginal microbiome-drug interactions affect antibiotic treatment for bacterial vaginosis, emphasizing the need for ...
Iterum Therapeutics plc (Nasdaq: ITRM) ('Iterum” or the 'Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant ...
As antibiotic-resistant "superbugs" make infections trickier to treat, some in the medical community are turning to ...
Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...
Researchers from the National University of Singapore (NUS) have solved a 60-year-old mystery in bacterial cell envelope ...
Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that the United States Patent and Trademark ...
Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing ...
(“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment ...
Background In 2011, there were approximately two million cases of hospital-acquired infections in the United States, more than 75,000 of which were fatal. [1] Gram-negative bacteria cause the four ...
Dr. Jennifer Schneider discusses Centauri Therapeutics' novel approach to combating Gram-negative infections, its first ...
A brain abscess is a rare but life-threatening infection. Learn how advances in imaging, surgery, and diagnostics are ...